CAESAREA, Israel and
NEW YORK, Nov. 14, 2019 /PRNewswire/ -- DarioHealth
Corp. (NASDAQ: DRIO) ("DarioHealth" or "Dario"), a
leading, global digital therapeutics company, today announced that
Dario's CEO, Erez Raphael, will be
participating in a panel discussion at BTIG Digital Health 2019:
Industry Innovators on What's Next, on Wednesday, November 20, 2019.
BTIG's one day event features panelists from established and
emerging digital health companies alongside influential payors. The
panel discussions will bring insights and views from digital health
industry innovators - including bridging big tech and healthcare to
address gaps; today's challenges; clinical evidence; developing
commercial models for prescription digital therapeutics; finding
the right partnerships; and the innovation gap.
DarioHealth will be participating in the panel discussion:
"Ensuring You Have the Right Amount of Clinical Evidence." During
the session, Mr. Raphael will discuss the need for quality
evidence-based therapeutic interventions backed up and grounded in
the appropriate level of clinically validated studies.
"I am excited to share my knowledge of how DarioHealth
implements evidence-based interventions into our digital solutions.
Digital therapeutics is rapidly emerging as a key area of future
healthcare. As with any disruptive health technology, successful
companies are those who earn credibility with evidence-based
results that support their solutions. With nine published
scientific studies, this is an area in which we believeDarioHealth
excels," said Erez Raphael, CEO of
DarioHealth. "Through our scientifically proven interventions,
Dario users show improvements in medical adherence and lifestyle
change, resulting in better management of their chronic conditions
and healthier outcomes."
About DarioHealth Corp.
DarioHealth Corp. (NASDAQ: DRIO) is a leading,
global digital therapeutics company revolutionizing the way
people with chronic conditions manage their health. By delivering
evidence-based interventions that are driven by data, high-quality
software and coaching, we empower individuals to make healthy
adjustments to their daily lifestyle choices to improve their
overall health. Our cross-functional team operates at the
intersection of life sciences, behavioral science and software
technology to deliver highly engaging therapeutic interventions.
Dario is one of the highest-rated diabetes solutions in the market,
and its user-centric MyDario™ mobile app is loved by tens of
thousands of consumers around the globe. DarioHealth is rapidly
moving into new chronic conditions and geographic markets, using a
performance-based approach to improve the health of users managing
chronic disease. To learn more about DarioHealth and its digital
health solutions, please go to: http://mydario.com/
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and
partners of DarioHealth Corp. (the "Company") related thereto
contain or may contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Statements that are not statements of historical fact may be deemed
to be forward-looking statements. Without limiting the generality
of the foregoing, words such as "plan," "project," "potential,"
"seek," "may," "will," "expect," "believe," "anticipate," "intend,"
"could," "estimate," or "continue" are intended to identify
forward-looking statements. For example, when the Company discusses
its belief that it excels as a succesful company with disruptive
health technology that has earned credibility with evidence-based
results that support its solutions, it is using forward-looking
statements. Readers are cautioned that certain important factors
may affect the Company's actual results and could cause such
results to differ materially from any forward-looking statements
that may be made in this news release. Factors that may affect the
Company's results include, but are not limited to, regulatory
approvals, product demand, market acceptance, impact of competitive
products and prices, product development, commercialization or
technological difficulties, the success or failure of negotiations
and trade, legal, social and economic risks, and the risks
associated with the adequacy of existing cash resources. Additional
factors that could cause or contribute to differences between the
Company's actual results and forward-looking statements include,
but are not limited to, those risks discussed in the Company's
filings with the U.S. Securities and Exchange Commission. Readers
are cautioned that actual results (including, without limitation,
the timing for and results of the Company's commercial and
regulatory plans for Dario) may differ significantly from those set
forth in the forward-looking statements. The Company undertakes no
obligation to publicly update any forward-looking statements,
whether as a result of new information, future events or otherwise,
except as required by applicable law.
DarioHealth Corporate Contact:
Claudia
Levi
Content & Communications Manager
claudia@mydario.com
+1-347-767-4220
View original
content:http://www.prnewswire.com/news-releases/dariohealth-corp-ceo-erez-raphael-invited-to-participate-in-btig-digital-health-2019-300958239.html
SOURCE DarioHealth Corp.